Assessment the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathy

Phase 3

Recruiting

• Conditions: chemotherapy-induced peripheral neuropathy in patients with cancer.; Idiopathic peripheral autonomic neuropathy; G90.0

• Registration Number: IRCT20160310026998N12
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

People with any malignancy who have had grade 2 or higher neuropathy following chemotherapy

Exclusion Criteria

Patients with hypertension
Acute heart failure
type 1 & 2 diabetes mellitus
peripheral vascular disease
285/5000Patients taking drugs (amantadine, ketamine, dextromethorphan, L-dopa; dopaminergic, anticholinergic agonists, barbiturates, neuroleptics, IMAO, antispasmodics, dantrolene or baclofen, phenytoinquinotine, cimetidine, ranitidine And warfarin)
alcohl use
People of reproductive ages, pregnancy and lactation
People taking other neuropathic medications such as gabapentin, pregabalin and dologestin
Patients with brain or leptomeningeal metastasis

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of neuropathic symptoms. Timepoint: At PRE intervention (baseline phase) & 8 weeks after intervention. Method of measurement: McGill pain questionnaire, Neuropathic Pain, Neuropathic Pain Symptom Inventory.